CSS
RLMD icon

Cubist Systematic Strategies’s Relmada Therapeutics RLMD Stock Holding History

Cubist Systematic Strategies’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-51,161
Closed -$238K – 3854
2024
Q1 		$238K Buy
+51,161
New +$247K ﹤0.01% 2998
2023
Q3 		– Sell
-15,477
Closed -$38.1K – 3833
2023
Q2 		$38.1K Sell
15,477
-22,024
-59% -$60.9K ﹤0.01% 3125
2023
Q1 		$84.8K Sell
37,501
-3,189
-8% -$11K ﹤0.01% 3473
2022
Q4 		$142K Buy
40,690
+5,565
+16% +$48.9K ﹤0.01% 3713
2022
Q3 		$1.3M Sell
35,125
-6,192
-15% -$172K 0.01% 2398
2022
Q2 		$785K Buy
41,317
+7,586
+22% +$165K ﹤0.01% 2671
2022
Q1 		$910K Buy
33,731
+32,822
+3,611% +$679K 0.01% 2103
2021
Q4 		$20K Sell
909
-13,151
-94% -$292K ﹤0.01% 3377
2021
Q3 		$369K Buy
14,060
+12,841
+1,053% +$344K ﹤0.01% 2227
2021
Q2 		$39K Buy
1,219
+1,190
+4,103% +$41.3K ﹤0.01% 2813
2021
Q1 		$1K Sell
29
-595
-95% -$20.8K ﹤0.01% 2800
2020
Q4 		$20K Sell
624
-314
-33% -$10.8K ﹤0.01% 2501
2020
Q3 		$35K Buy
+938
New +$36.3K ﹤0.01% 2386

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cubist Systematic Strategies's RLMD Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 51,161 shares — an estimated $238K sold.

Cubist Systematic Strategies first reported a position in RLMD in Q3 2020 and held it in 13 quarters. The position peaked at $1.3M in Q3 2022. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 51,161 Relmada Therapeutics shares in Q2 2024, an estimated $238K.
  • Cubist Systematic Strategies first reported a position in Relmada Therapeutics in Q3 2020 and held it in 13 quarters.
  • Cubist Systematic Strategies's Relmada Therapeutics position peaked at $1.3M in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.